A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: BI 1584862; Drug: Placebo

• Registration Number: NCT06148948
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The goal of this trial is to investigate safety, tolerability and pharmacokinetics of BI 1584862 in healthy male subjects of Japanese ethnicity following oral administration of single rising doses.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-11-20
• Study First Submitted QC: 2023-11-20
• Study First Posted: 2023-11-28
• Study Start: 2023-12-25
• Primary Completion: 2024-05-21
• Study Completion: 2024-05-21
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-12
• Last Update Posted: 2024-11-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 32

Inclusion Criteria

1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs blood pressure (BP) and pulse rate (PR), 12-lead electrocardiogram (ECG), and clinical laboratory tests at screening visit.

2. Japanese ethnicity, according to the following criteria: born in Japan, have lived outside of Japan <10 years, and have parents and grandparents who are Japanese

3. Age of 18 to 45 years (inclusive) at screening visit.

4. Body mass index (BMI) of 18.5 to 24.9 kg/m^2 (inclusive) at screening visit.

5. Signed and dated written informed consent in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial

6. Subjects who agree to minimise the risk of making their partner pregnant by fulfilling any of the following criteria starting from the start of trial medication until 90 days after the last medication:

   • Use of adequate contraception, any of the following methods plus condom: intrauterine device, combined oral contraceptives that started at least 2 months prior to the first drug administration
   • Vasectomized (vasectomy at least 1 year prior to enrolment)
   • Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy) of the subject's female partner
   • Female partner is postmenopausal, defined as no menses for 1 year without an alternative medical cause

Exclusion Criteria

1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit.
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg) , diastolic blood pressure outside the range of 40 to 99 mmHg, or pulse rate outside the range of 40 to 99 beats per minute (bpm) at screening visit.
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance at screening visit.
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BI 1584862 dose group 3	BI 1584862	Group receiving dose 3 of BI 1584862
Placebo	Placebo	Placebo matching BI 1584862
BI 1584862 dose group 4	BI 1584862	Group receiving dose 4 of BI 1584862
BI 1584862 dose group 1	BI 1584862	Group receiving dose 1 of BI 1584862
BI 1584862 dose group 2	BI 1584862	Group receiving dose 2 of BI 1584862

Primary Outcome Measures

Name	Time	Method
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator	Up to day 10

Secondary Outcome Measures

Name	Time	Method
Area under the concentration-time curve of plasma BI 1584862 over the time interval from 0 to the last quantifiable data point (AUC0-tz)	Up to day 4
Maximum measured concentration of BI 1584862 in plasma (Cmax)	Up to day 4

Trial Locations

Locations (1)

SOUSEIKAI Sumida Hospital; 🇯🇵 Tokyo, Sumida-ku, Japan